DEXWireNews

ACRX - Perfect Trend Bounce 0.168 Levels On Daily

Pembelian
NASDAQ:ACRX   None
AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

SHORT INTEREST
15.09M 07/15/19

Average Recommendation: BUY

Average Target Price: 7.71

P/E Current
-3.02

P/E Ratio (with extraordinary items)
-3.90

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our Mobile App >>

Android: dexwirenews.com/APP

Apple: dexwirenews.com/iOS

2) Join our Telegram >> t.me/DEXWireNews

3) Follow @DEXWireNews on Social Media
Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.